Business Context and Reporting Period
This Form 8-K Current Report was filed by Capricor Therapeutics, Inc. on April 14, 2016. The filing addresses corporate governance changes regarding the Board of Directors ahead of the Company's 2016 Annual Meeting of Stockholders scheduled for June 2, 2016.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change disclosed is the departure of Gregory W. Schafer from the Board of Directors. Mr. Schafer has notified the Company that he will not stand for re-election when his term expires at the Annual Meeting. He will continue to serve as a Board member, Chairman of the Audit Committee, and member of the Nominating and Corporate Governance Committee until the meeting concludes.
Guidance, Outlook, and Risks
Management commentary confirms that Mr. Schafer's decision not to seek re-election is not due to any disagreement with the Company regarding its operations, policies, or practices. The filing does not provide financial guidance, outlook, or discuss specific risks or contingencies beyond the standard disclosure of the director's departure.
Key Facts for Investor Verification
- Gregory W. Schafer will not stand for re-election at the June 2, 2016 Annual Meeting.
- Mr. Schafer remains on the Board and in his committee roles until the Annual Meeting.
- The departure is explicitly stated as not being caused by any disagreement with the Company.
- No financial results or operational metrics are included in this specific filing.